{"filing":{"accession_number":"0001778922-26-000052","cik":"0001778922","ticker":"SGP","company_name":"SpyGlass Pharma, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"sgp-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm"},"events":[{"id":36077,"run_id":33262,"accession_number":"0001778922-26-000052","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"SpyGlass Pharma disclosed positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, showing 37% IOP reduction, 86% of patients off topical drops, and no product-related adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate advancing toward Phase 3 trials and potential NDA submission, but it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone that would affect investor assessment of the company's pipeline progress.","company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40357,"accession_number":"0001778922-26-000052","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SpyGlass Pharma disclosed positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, showing 37% IOP reduction, 86% of patients off topical drops, and no product-related adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate advancing toward Phase 3 trials and potential NDA submission, but it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:11:39.541368+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40357,"accession_number":"0001778922-26-000052","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SpyGlass Pharma disclosed positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, showing 37% IOP reduction, 86% of patients off topical drops, and no product-related adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate advancing toward Phase 3 trials and potential NDA submission, but it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant product development milestone that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:11:39.541368+00:00","company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","filing_date":"2026-10-19"}]}